Australia markets closed

    +59.80 (+0.87%)

    +0.0010 (+0.14%)
  • ASX 200

    +57.60 (+0.86%)
  • OIL

    +1.73 (+1.58%)
  • GOLD

    +1.50 (+0.08%)

    -441.44 (-1.43%)
  • CMC Crypto 200

    -0.84 (-0.18%)

Riverain Technologies™ will Showcase Enhancements to its AI Platform for Lung Nodule Detection at RSNA

·2-min read

ClearRead CT and X-ray Applications, the Most Clinically Validated in the Industry, Help Maintain Efficiency, Accuracy and Consistency in Lung Cancer Screening

CHICAGO, November 29, 2021--(BUSINESS WIRE)--Riverain Technologies, a leader in artificial intelligence (AI) for early, efficient detection of lung nodules, will showcase its solutions and enhancements at the 107th Annual Radiological Society of North America (RSNA) meeting, November 28-December 2, 2021 (South Hall #4129).

Key workflow enhancements are focused on improving the clinical user experience through tighter integration into site clinical processes for streamlined and more efficient reporting. For example, Fleischner and Lung-RADS scores can be customized to institutional or provider preferences and included in the case level summary report. Nodules can be sorted based on diameter, mass, volume, doubling time, etc. Standardized reports have been revised for configurability, language and readability with a configurable PDF output.

Clinical improvements to ClearRead solutions that continue to push the frontiers of nodule detection accuracy will be demonstrated for the first time. Nodule detection enhancements include enhanced performance on mediastinal nodules, nodule typing and nodule matching for better workflow.

In addition, the company will showcase updates to system service capabilities, making it easier for in-house teams to manage more service onsite.

For more information or to schedule an appointment, visit Riverain/RSNA.

ClearRead CT applications are approved for concurrent reading, saving radiologists time and steps in enhanced image review. The ClearRead suite significantly improves a clinician's ability to accurately and efficiently detect disease using patented vessel (CT) and bone (X-ray) suppression technology in thoracic images—for earlier, more efficient detection of lung abnormalities.

"As our installed base continues to expand and customers implement enterprise level solutions, improvements to enhance clinical accuracy as well as efficient reporting are critical for optimized workflows. ClearRead tools utilize increased automation to help radiologists improve the efficiency of disease detection, diagnosis, reporting, and treatment," said Mark Koeniguer, Chief Commercial Officer at Riverain Technologies.

About Riverain Technologies

Riverain is dedicated to the early, efficient detection of lung disease. Riverain believes the opportunities for machine learning and software solutions in healthcare are at an unprecedented level. Never before has the opportunity to 'do more with less' been so great. We believe tools incorporating increasing degrees of intelligence will facilitate decision making, leading to improved patient outcomes. For more information, please visit

View source version on


Chris K. Joseph

Sanmitra Iwanski

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting